In this study, we evaluated HER3 expression in matched-paired specimens taken from gynecological cancer patients at initial and recurrent diagnosis to evaluate HER3 as a promising biomarker for overcoming treatment failure and improving patient outcomes. This evidence concerns the gene ERBB3 and female reproductive organ cancer.